Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. Co. has developed a resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL, has various potential indications of use for diseases, which of Co. is primarily targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome and with Amyotrophic Lateral Sclerosis in an early development stage. In the larger disease areas, Co. is primarily targeting Mild Cognitive Impairment/early Alzheimer's disease with Traumatic Brain Injury /concussions and Covid-19 in early development stages. The JUNS average annual return since 2024 is shown above.
The Average Annual Return on the JUNS average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether JUNS average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the JUNS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|